Introduction
The emergence and steady spread of antibiotic-resistant bacterial pathogens are global public health concerns. In particular, the rapid rise of antibiotic resistance among Streptococcus pneumoniae has complicated the therapy of pneumococcal infections both in adults and children [1] [2] [3] [4] . Therapeutic strategies for combating antibiotic-resistant pneumococcal infections are currently being explored, including the possibility of reviving old active drugs. Novobiocin, an aminocoumarin natural product elaborated by streptomycetes, was widely used as an antibacterial agent in the 1950s and 1960s. Novobiocin is an inhibitor of bacterial DNA gyrase. Like other coumarin products, it binds more tightly to gyrase (as reflected by equilibrium dissociation constants in the range of 10 nM [7] ) than do typical quinolones, and novobiocin also causes inhibition of ATP binding [8] . Novobiocin was used for the treatment of a variety of infections caused by susceptible organisms, including pneumococcal pneumonia [9] . However, several reports published in the 1950s regarding the emergence of resistance and side effects [10] [11] [12] , along with the development of other antibiotics (i.e. penicillinase-resistant penicillins), likely determined the lack of usage of this otherwise potent and inexpensive antibiotic.
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The aims of this study were to investigate the in vitro activity, pharmacokinetics and effectiveness of novobiocin therapy using a murine sepsis model caused by amoxicillin-susceptible and -resistant S. pneumoniae strains.
Material and methods

Bacterial strains and antibiotics
Four clinical strains of S. pneumoniae were used in this study, for which the serotype, origin and penicillin minimum inhibitory concentration (MIC) were as follows: strain AR33118, serotype 3, blood, MIC = 0.015 mg/L; strain MJD3693, g; GlaxoSmithKline S.A.) were used for in vitro and in vivo studies, respectively.
Minimum inhibitory concentrations and time-kill analysis
MICs of novobiocin and amoxicillin for the various strains were determined by the microdilution method approved by the Clinical and Laboratory Standards Institute (CLSI) [13] using cation-adjusted Mueller-Hinton II broth (Becton, Dickinson and Co., Le Pont-de-Claix, France) supplemented with 4% lysed horse blood (CA-MHB-LHB). Modal values of three separate determinations were considered.
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A c c e p t e d M a n u s c r i p t 6 Time-kill assays were performed by exposing cultures of the various strains to novobiocin or amoxicillin at 2, 8 or 32 MIC, except for the strain that was most resistant to penicillin (strain SPC2552) for which the amoxicillin concentration of 32 MIC was not tested owing to poor solubility of the powder.
Bacteria were grown in broth to early log phase and then inoculated tubes with CA-MHB-LHB were incubated at 35 C in normal atmosphere at a final titre of 2  10 6 colony-forming units (CFU)/mL. Samples of 100 L were removed at the time of inoculation (time zero) and after 2 h and 5 h, diluted and plated on blood agar plates for colony counting. The killing effects of antibiotics were thus compared by determining the change in log 10 CFU/mL at 2 h and 5 h compared with counts in the control tubes at each time point, and such differences in bacterial titres were expressed as negative values. Antibiotic carryover was minimised by dilution. Each test was performed in duplicate.
Mouse sepsis model
Experimental animals were adult female Swiss mice weighing 30  2 g (Centro 
Treatment protocols
Treatment of mice was performed as a subcutaneous (s.c.) injection in a volume of 0.1 mL per dose in the neck region. For the efficacy studies, four doses of antibiotics were given at 1, 5, 24 and 48 h after infection, and survival was recorded daily throughout the study period, which ended 72 h after inoculation. At the end of the study, animals were euthanised by CO 2 overdose, and peritoneal lavage fluid specimens were collected and processed for CFU determination. Peritoneal lavage was also performed post-mortem in animals that were found dead before finishing the experiment. The results of peritoneal bacterial load were expressed as mean ± standard deviation (S.D.) log 10
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A c c e p t e d M a n u s c r i p t 8 CFU/mL. Differences in the number of CFU/mL between treated and control animals were calculated to compare the effectiveness of the treatment regimens. The lower limit of organism quantification in these studies was 10 CFU/mL.
Two types of experiments were performed to evaluate the effectiveness of antibiotic therapy, and the most effective antimicrobial regimen was defined as the regimen that achieved the highest survival rate and the most potent antibacterial effect in the peritoneal fluid.
Drug effectiveness in sepsis caused by a penicillin-susceptible strain
Mice with sepsis induced by the penicillin-susceptible strain (AR33118) received novobiocin (25, 50, 100 or 200 mg/kg) or amoxicillin (25 mg/kg). A group of mice received apyrogen sterile distilled water as control for the lethality and the peritoneal bacterial load of the infection. Mostly, five to seven mice were used for each regimen in these dose-ranging experiments.
Drug effectiveness in sepsis caused by penicillin-resistant strains
Following infection with each of the three penicillin-resistant S. pneumoniae strains, mice were treated with doses of novobiocin at 100 mg/kg or 200 mg/kg or amoxicillin at 50 mg/kg or 200 mg/kg. A group of mice that received apyrogen sterile distilled water was tested as control. Each regimen was given to mice in groups of at least seven animals (range, seven to ten animals). Survival was noted daily and peritoneal bacterial loads were determined as above.
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A c c e p t e d M a n u s c r i p t ATCC 9341 as the test organism [14] . The antibiotic concentration in both parts (total plasma and protein-free ultrafiltrate) was calculated using standard curves derived from solutions prepared with different antibiotic concentrations dissolved, respectively, in pooled mouse plasma and 0.9% NaCl. Analyses were performed in duplicate and the intraday and interday variation was <10%.
PK analysis of novobiocin in total plasma and plasma ultrafiltrate was performed weeks. In addition, the aspect (once a week) and survival of mice were observed for 4 months. Dunn's multiple-comparisons test among groups when they were significantly different. Culture-negative samples (<10 CFU/mL) were included in the calculation of means assuming a value at the detection limit (1.0 log 10 CFU/mL).
Data analysis
A P-value of <0.05 was considered significant.
Results
Minimum inhibitory concentrations and time-kill curves
Novobiocin and amoxicillin MICs, respectively, of the study organisms were as A c c e p t e d M a n u s c r i p t
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Time-kill data for the four S. pneumoniae strains are presented in Table 1 .
Baseline inocula ranged from 6.03 log 10 CFU/mL to 6.75 log 10 CFU/mL (time zero). Novobiocin exposure resulted in a >2 log 10 difference in viable counts versus the controls for all strains and all concentrations tested by 5 h, except for strains AR33118 and SPC2162 at 2 MIC. The antibacterial effect of amoxicillin was more potent and rapid than that of novobiocin, achieving at 2 MIC a >2 log 10 difference by 2 h and >4 log 10 difference by 5 h, but this effect was somewhat lower for the most resistant strain (SPC2552). As shown in Table 1, for novobiocin there was an increase in killing by increasing concentrations on MIC basis as well as on time basis by comparing 2 h vs. 5 h.
Therapeutic efficacy in sepsis caused by amoxicillin-susceptible andresistant strains
The in vivo efficacy of novobiocin against amoxicillin-susceptible and -resistant S. pneumoniae strains in a mouse sepsis model is shown in Fig. 1 . With the treatment schedule consisting of four s.c. doses at 1, 5, 24 and 48 h after infection, both novobiocin 200 mg/kg and amoxicillin 25 mg/kg were associated with a 100% survival rate of mice infected with the amoxicillin-susceptible strain AR33118 (P < 0.01 vs. untreated control group). For this strain, novobiocin 100 mg/kg achieved a 71% survival rate.
With the amoxicillin-resistant strains, novobiocin 200 mg/kg achieved the highest protection (90-100% survivors), followed by amoxicillin 200 mg/kg (60-100%), and these differences were statistically significant (P < 0.01) compared
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A c c e p t e d M a n u s c r i p t 12 with the controls, except for the group infected with strain SPC2162 and treated with amoxicillin 200 mg/kg, which had a 60% survival rate. Novobiocin 100 mg/kg protected 50-87.5% of the animals, whereas amoxicillin 50 mg/kg protected only 14.3-25% of the animals, with the lowest survival rate in animals infected with the most resistant strain (SPC2552). Notably, against this strain the 200 mg/kg amoxicillin regimen gave protection (87.5% survivors) similar to that showed by novobiocin 100 mg/kg. Table 2 shows the peritoneal bacterial counts after therapy with novobiocin and amoxicillin regimens in mice with sepsis induced by four pneumococcal strains that were survivors and were humanely sacrificed for sampling at 72 h after infection or animals that died before 72 h. All control animals that died had >8 log 10 CFU/mL in the peritoneum (mean value 8.7 log 10 CFU/mL, range 8.2-9.1 log 10 CFU/mL).
All mice infected with the amoxicillin-susceptible strain (AR33118) and treated with both novobiocin 200 mg/kg and amoxicillin 25 mg/kg survived, and the bacterial load in the peritoneum was undetectable, whereas the mean decline in peritoneal bacterial counts of survivor mice treated with novobiocin 100 mg/kg compared with those of the control group was only 1.7 log units. 
Novobiocin pharmacokinetics and tolerance
Single-dose PK studies performed in non-infected mice that received single s.c. 
Discussion
Multidrug-resistant and highly antibiotic-resistant pneumococci have emerged as significant pathogens causing community-acquired infections worldwide [15] .
However, following the 2008 CLSI parenteral penicillin breakpoints for nonmeningitis pneumococcal isolates (intermediate, 4 mg/L; resistant, 8 mg/L) [13] , there are few up-to-date published studies dealing with highly -lactamresistant pneumococci (penicillin MIC ≥ 8 mg/L), especially regarding their optimal antibiotic therapy [16] [17] [18] . Among therapeutic strategies for combating pneumococcal infections caused by highly -lactam-resistant strains, here we have explored the use of novobiocin, an old drug, which we hypothesise could be re-introduced to the antibiotic armamentarium specifically for therapy of pneumococcal infections caused by strains with high-level resistance to the clinically used antibiotics.
Novobiocin was extensively used before the development of broad-spectrum agents such as -lactam and quinolone agents. Because novobiocin displays potent activity against staphylococci, including meticillin-resistant
Staphylococcus aureus (MRSA), pneumococci, enterococci and many other
Gram-positive organisms [5, 6] , during the 1980s the suitability of clinical reevaluation of this drug was suggested [6] . Clinical trials conducted in the 1990s demonstrated the efficacy of novobiocin-containing combinations for eradicating the carrier state of MRSA [19, 20] . Indeed, novobiocin combined with rifampicin prevented the development of resistance in MRSA to either drug even more efficiently than the combination of co-trimoxazole and rifampicin [20] .
Remarkably, among severely ill patients with haematological disorders, the A c c e p t e d M a n u s c r i p t 15 combination of novobiocin with doxycycline or rifampicin was effective for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia [21] .
Regarding the side effects associated with the use of novobiocin alone or in combination, it should be stressed that many patients [19, 20, 22] and healthy volunteers [23, 24] received this drug, mostly at 500 mg every 12 h for a variable period of time, without reporting relevant toxicity, and it has been suggested that some of the side effects could be attributed to impurities in the formulation that have since been removed [20] . Besides, novobiocin has also been administered as a modulator of alkylating agent cytotoxicity combined with cyclophosphamide, with the maximum tolerated dose being 6 g/day of novobiocin [25] .
The in vitro results using time-kill curves show that the antibacterial effect of amoxicillin is more potent and rapid than that of novobiocin but the A c c e p t e d M a n u s c r i p t
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The doses selected for amoxicillin administration were based on the results from a previous study by our group [26] which showed that the maximum amoxicillin concentrations attained in mouse serum after single doses of amoxicillin of 200 mg/kg and 50 mg/kg were 300 mg/L and 75 mg/L, respectively. However, such high amoxicillin concentrations cannot be achieved in patients following oral administration of usual dosages. In fact, peak levels of amoxicillin of 7.5 mg/L and 4 mg/L in the blood of patients occur 2 h after ingestion of 500 mg and 250 mg doses taken fasting, respectively [27, 28] , so only a high dose of this drug administered parenterally could achieve a peak serum concentration closed to 100 mg/L. On the other hand, a PK study carried out in humans, as determined by HPLC, showed that after ingestion of novobiocin at 500 mg every 12 h the mean peak serum concentration was 62.5 A c c e p t e d M a n u s c r i p t 17 al. [29] described that a specific amino acid change (Ser-127Leu) in the DNA gyrase B subunit of S. pneumoniae increases novobiocin resistance, with MICs of 1 mg/L to 128 mg/L for the novobiocin-susceptible and -resistant strain, respectively.
In conclusion, until novel antibacterial agents are discovered, our in vitro and in vivo data suggest that novobiocin may be a therapeutic alternative in pneumococcal infections caused by highly -lactam-resistant strains. 
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